Behr Jürgen, Berger Melanie, Blum Torsten Gerriet, Bonella Francesco, Dinkel Julien, Gläser Sven, Hagmeyer Lars, Kneidinger Nikolaus, Koschel Dirk, Prasse Antje, Slevogt Hortense, Stacher-Priehse Elvira, Woehrle Holger, Kreuter Michael
Medizinische Klinik und Poliklinik V, LMU Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (DZL), München, Deutschland.
Lungenklinik Köln-Merheim und Lehrstuhl für Pneumologie, Universität Witten/Herdecke, Kliniken der Stadt Köln gGmbH, Köln, Deutschland.
Pneumologie. 2023 Mar;77(3):143-157. doi: 10.1055/a-2007-9845. Epub 2023 Mar 14.
The SARS-CoV-2 pandemic had a tremendous impact on diagnosis and treatment of interstitial lung diseases (ILD). Especially in the early phase of the pandemic, when the delta variant was prevailling, a huge number of viral pneumonias were observed, which worsened pre-existing, triggered de novo occurence or discovery of previously subclincal interstitial lung diseases. The effect of SARS-CoV-2 infection - without or with accompanying viral pneumonia - on the further development of pre-existing ILD as well of new pulmonary inflitrates and consolidiations is difficult to predict and poses a daily challenge to interdisciplinary ILD boards. This position paper of the German Respiratory Society (DGP e.V.) provides answers to the most pressing questions based on current knowledge.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)大流行对间质性肺疾病(ILD)的诊断和治疗产生了巨大影响。特别是在大流行的早期阶段,当德尔塔变种盛行时,观察到大量病毒性肺炎,这使先前存在的间质性肺疾病恶化、引发了新发疾病或发现了先前亚临床的间质性肺疾病。SARS-CoV-2感染(无论有无伴发病毒性肺炎)对先前存在的ILD以及新的肺部浸润和实变的进一步发展的影响难以预测,并且每天都给跨学科ILD委员会带来挑战。德国呼吸学会(DGP e.V.)的这份立场文件基于当前知识对最紧迫的问题给出了答案。